[
  {
    "ts": "2026-01-02T13:00:00+00:00",
    "headline": "Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026",
    "summary": "NEW BRUNSWICK, N.J., January 02, 2026--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company’s common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026.",
    "url": "https://finance.yahoo.com/news/johnson-johnson-announces-quarterly-dividend-130000105.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "38d59e6b-b21d-30f0-ae81-512af0ffcff1",
      "content": {
        "id": "38d59e6b-b21d-30f0-ae81-512af0ffcff1",
        "contentType": "STORY",
        "title": "Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026",
        "description": "",
        "summary": "NEW BRUNSWICK, N.J., January 02, 2026--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company’s common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026.",
        "pubDate": "2026-01-02T13:00:00Z",
        "displayTime": "2026-01-02T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/74a9e750bb8572f50815990ad770f04d",
          "originalWidth": 2404,
          "originalHeight": 224,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9D1mpPDKtEJFX_di8FaeFg--~B/aD0yMjQ7dz0yNDA0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/74a9e750bb8572f50815990ad770f04d.cf.webp",
              "width": 2404,
              "height": 224,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2NCiUkEfmLMn4cQk9Xo6zQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/74a9e750bb8572f50815990ad770f04d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-announces-quarterly-dividend-130000105.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-announces-quarterly-dividend-130000105.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-02T12:44:00+00:00",
    "headline": "Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth",
    "summary": "ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.",
    "url": "https://finance.yahoo.com/news/heres-abbvies-neuroscience-portfolio-aiding-124400302.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2a65e28b-177a-31e6-97a1-3357440a62c2",
      "content": {
        "id": "2a65e28b-177a-31e6-97a1-3357440a62c2",
        "contentType": "STORY",
        "title": "Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth",
        "description": "",
        "summary": "ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.",
        "pubDate": "2026-01-02T12:44:00Z",
        "displayTime": "2026-01-02T12:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OQG3.5Wd9P9R69q2rhm9rA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pBlncPVBhEXpjxtBDlEOsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-abbvies-neuroscience-portfolio-aiding-124400302.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-abbvies-neuroscience-portfolio-aiding-124400302.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-02T14:51:00+00:00",
    "headline": "Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China",
    "summary": "Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.",
    "url": "https://finance.yahoo.com/news/spotlight-health-etfs-nvo-lly-145100642.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "bb9f3282-49ac-31b5-a467-31f9dc7f4c90",
      "content": {
        "id": "bb9f3282-49ac-31b5-a467-31f9dc7f4c90",
        "contentType": "STORY",
        "title": "Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China",
        "description": "",
        "summary": "Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.",
        "pubDate": "2026-01-02T14:51:00Z",
        "displayTime": "2026-01-02T14:51:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/e66aa7ee2b50b297307d131c5d457a73",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3GkkLZFYbl52wnpptRqd1w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e66aa7ee2b50b297307d131c5d457a73.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a7SzRmhAvDPGiiSvT8MWFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e66aa7ee2b50b297307d131c5d457a73.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/spotlight-health-etfs-nvo-lly-145100642.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/spotlight-health-etfs-nvo-lly-145100642.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "VHCIX"
            },
            {
              "symbol": "VHT"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PPH"
            },
            {
              "symbol": "IYH"
            },
            {
              "symbol": "IXJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "NVSEF"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]